NATCO Pharma 将来の成長

Future 基準チェック /06

NATCO Pharmaの収益と利益は、それぞれ年間9.4%と30.7%減少すると予測されています。EPS は年間30.4%で減少すると予想されています。自己資本利益率は 3 年後に11.1%になると予測されています。

主要情報

-30.7%

収益成長率

-30.37%

EPS成長率

Pharmaceuticals 収益成長	14.9%
収益成長率	-9.4%
将来の株主資本利益率	11.15%
アナリストカバレッジ	Good
最終更新日	06 May 2025

今後の成長に関する最新情報

NATCO Pharma Limited (NSE:NATCOPHARM) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers

Feb 16

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15

Recent updates

There's No Escaping NATCO Pharma Limited's (NSE:NATCOPHARM) Muted Earnings

May 22

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Mar 24

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Mar 09

Analysts Are More Bearish On NATCO Pharma Limited (NSE:NATCOPHARM) Than They Used To Be

Feb 19

NATCO Pharma Limited (NSE:NATCOPHARM) Not Doing Enough For Some Investors As Its Shares Slump 30%

Feb 18

NATCO Pharma Limited (NSE:NATCOPHARM) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers

Feb 16

Future Revenue Will Decline As Competition Erodes Revlimid Pricing And R&D Costs Compress Margins

Feb 09 Uncertainty in pricing and revenue from Revlimid could impact net margins and limit R&D expenditure.

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Oct 13

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

May 09

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20

業績と収益の成長予測

NSEI:NATCOPHARM - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	32,816	7,113	9,395	N/A	10
3/31/2026	50,323	19,018	15,294	N/A	10
3/31/2025	45,752	19,467	14,161	N/A	10
12/31/2024	42,800	18,651	N/A	N/A	N/A
9/30/2024	45,638	19,448	12,838	17,163	N/A
6/30/2024	43,490	16,365	N/A	N/A	N/A
3/31/2024	40,020	13,883	8,529	12,116	N/A
12/31/2023	38,298	12,778	N/A	N/A	N/A
9/30/2023	35,637	11,274	5,230	7,477	N/A
6/30/2023	29,630	8,152	N/A	N/A	N/A
3/31/2023	27,085	7,153	6,435	8,491	N/A
12/31/2022	24,074	3,890	N/A	N/A	N/A
9/30/2022	24,754	4,071	5,575	8,302	N/A
6/30/2022	24,191	4,154	N/A	N/A	N/A
3/31/2022	19,462	1,700	-1,962	465	N/A
12/31/2021	16,833	2,735	N/A	N/A	N/A
9/30/2021	14,780	2,558	-2,457	230	N/A
6/30/2021	18,990	3,931	N/A	N/A	N/A
3/31/2021	20,561	4,409	465	2,988	N/A
12/31/2020	21,756	4,820	N/A	N/A	N/A
9/30/2020	23,026	5,238	1,554	4,466	N/A
6/30/2020	19,861	4,404	N/A	N/A	N/A
3/31/2020	19,150	4,608	587	4,173	N/A
12/31/2019	19,159	4,875	N/A	N/A	N/A
9/30/2019	19,904	5,425	-2,200	1,600	N/A
6/30/2019	20,482	6,060	N/A	N/A	N/A
3/31/2019	20,945	6,444	2,071	6,688	N/A
12/31/2018	24,066	8,235	N/A	N/A	N/A
9/30/2018	24,121	8,815	N/A	N/A	N/A
6/30/2018	22,953	7,838	N/A	N/A	N/A
3/31/2018	21,848	6,962	N/A	4,636	N/A
12/31/2017	19,817	5,730	N/A	N/A	N/A
9/30/2017	20,895	5,506	N/A	4,985	N/A
6/30/2017	21,679	5,323	N/A	N/A	N/A
3/31/2017	20,202	4,860	N/A	3,458	N/A
12/31/2016	17,697	3,680	N/A	N/A	N/A
9/30/2016	13,692	2,113	N/A	N/A	N/A
6/30/2016	12,431	1,748	N/A	N/A	N/A
3/31/2016	10,423	1,549	N/A	1,122	N/A
12/31/2015	9,355	1,494	N/A	N/A	N/A
9/30/2015	8,549	1,266	N/A	N/A	N/A
6/30/2015	8,390	1,294	N/A	N/A	N/A
3/31/2015	7,305	1,293	N/A	927	N/A
12/31/2014	8,089	1,042	N/A	N/A	N/A
9/30/2014	8,108	1,199	N/A	N/A	N/A
6/30/2014	7,648	1,144	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NATCOPHARMの収益は今後 3 年間で減少すると予測されています (年間-30.7% )。

収益対市場: NATCOPHARMの収益は今後 3 年間で減少すると予測されています (年間-30.7% )。

高成長収益: NATCOPHARMの収益は今後 3 年間で減少すると予測されています。

収益対市場: NATCOPHARMの収益は今後 3 年間で減少すると予想されています (年間-9.4% )。

高い収益成長: NATCOPHARMの収益は今後 3 年間で減少すると予測されています (年間-9.4% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NATCOPHARMの自己資本利益率は、3年後には低くなると予測されています ( 11.1 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/22 06:16
終値	2025/05/22 00:00
収益	2024/12/31
年間収益	2024/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

NATCO Pharma Limited 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。29

アナリスト	機関
Nitin Bhasin	Ambit Capital
Prashant Nair	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited

NATCO Pharma 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

NATCO Pharma Limited (NSE:NATCOPHARM) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers

Consensus EPS estimates increase by 11%

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

Consensus EPS estimates increase by 14%

Recent updates

There's No Escaping NATCO Pharma Limited's (NSE:NATCOPHARM) Muted Earnings

NATCO Pharma Limited to Report Q4, 2025 Results on May 28, 2025

New minor risk - Share price stability

NATCO Pharma Limited Provides Legal Update Regarding Risdiplam Launch in India

NATCO Pharma Limited Announces Superannuation of Ramesh Dandala, Executive Vice President - Technology Transfer, Intellectual Property Rights & Regulatory Affairs

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited Appoints Bhimrao Dattu Jadhav as Senior Vice President ­ Operations (Formulations)

Investor sentiment deteriorates as stock falls 33%

Analysts Are More Bearish On NATCO Pharma Limited (NSE:NATCOPHARM) Than They Used To Be

NATCO Pharma Limited (NSE:NATCOPHARM) Not Doing Enough For Some Investors As Its Shares Slump 30%

NATCO Pharma Limited (NSE:NATCOPHARM) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers

New minor risk - Share price stability

Dividend increased to ₹1.50

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Announces Resignation of Pavan Ganapati Bhat as Director & Executive Vice President (Technical Operations)

Lupin Limited and Natco Pharma Limited Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension

NATCO Pharma Limited Announces Final Approval of Its ANDA for Bosentan Tablets for Oral Suspension (TFOS), 32Mg

Future Revenue Will Decline As Competition Erodes Revlimid Pricing And R&D Costs Compress Margins

Now 20% overvalued

NATCO Pharma Limited to Report Q3, 2025 Results on Feb 12, 2025

Insider recently sold ₹3.5m worth of stock

Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings

Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?

Consensus EPS estimates increase by 11%

NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Dividend of ₹1.50 announced

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report First Half, 2025 Results on Nov 12, 2024

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Insider recently sold ₹30m worth of stock

High number of new directors

Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration

Less than half of directors are independent

New minor risk - Insider selling

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Board Member recently sold ₹6.0m worth of stock

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Investor sentiment improves as stock rises 21%

Consensus EPS estimates increase by 14%

Price target increased by 9.1% to ₹1,064

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

New major risk - Revenue and earnings growth

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Now 22% undervalued

Now 20% undervalued

Consensus EPS estimates increase by 17%

Investor sentiment improves as stock rises 16%

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Upcoming dividend of ₹1.25 per share

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited Appoints Bhimrao Dattu Jadhav as Senior Vice President Operations (Formulations)